Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04839965 · ClinicalTrials.gov registry record · Phase 2
Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen
A Phase 2 study, sponsored by Ampio Pharmaceuticals..
- Terminated
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT04839965: Clinical Trial Phase 2 study, sponsored by Ampio Pharmaceuticals..
NCT04839965 is a Phase 2 study that was terminated before completion, run by Ampio Pharmaceuticals.. The registered enrollment target is 36 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04839965, a Phase 2 study, was terminated before completion, sponsored by Ampio Pharmaceuticals..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is a Phase 2 randomized study to evaluate the safety and efficacy of IV Ampion in improving the clinical course and outcomes of adult COVID-19 patients requiring supplemental oxygen.
Primary Outcome
Assess the effect of Ampio compared to placebo on prevention of need for mechanical ventilation or death. This is measured as the occurrence of subjects on mechanical ventilation or death by day 28.
Interventions
- OTHER Saline
- BIOLOGICAL Ampion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2021-07-05 |
| Est. Completion | 2022-04-04 |
| Phase | Phase 2 |
Why NCT04839965 stopped before completion
NCT04839965 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT04839965 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04839965 about?
NCT04839965 is a clinical study titled "Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen". This is a Phase 2 randomized study to evaluate the safety and efficacy of IV Ampion in improving the clinical course and outcomes of adult COVID-19 patients requiring supplemental oxygen.
What is the current status of trial NCT04839965?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2021-07-05. Estimated completion is 2022-04-04.
What interventions are being tested in trial NCT04839965?
The interventions under investigation include: Saline (OTHER), Ampion (BIOLOGICAL).
Who is sponsoring clinical trial NCT04839965?
This trial is sponsored by Ampio Pharmaceuticals., which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04839965's enrollment target sits among peer trials
36 1496th of 2000 higher than 477 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI